
Mankind Pharma to launch IPO this month; looks to raise around ₹4,700 cr
The IPO of the country’s fourth largest pharma company by domestic sales comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.
The IPO of the country’s fourth largest pharma company by domestic sales comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.
Budget allotted ₹89,160 crore for healthcare sector for FY2024, less than 3% increase from previous year. In FY23, spending on healthcare was only 2.1% of GDP.
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
The domestic formulations market is expected to grow 7-9% this fiscal.